Aadi Bioscience, Inc. (AADI) Bundle
An Overview of Aadi Bioscience, Inc. (AADI)
General Summary of Aadi Bioscience, Inc. (AADI)
Aadi Bioscience, Inc. is a biopharmaceutical company focused on developing targeted therapies for rare cancers. The company's primary focus is on developing precision medicines for patients with specific genetic mutations.
Company Products and Services
Key product: FYARRO (sirolimus protein-bound particles for injectable suspension), approved for patients with locally advanced or metastatic malignant perivascular epithelioid cell tumor (PEComa).
| Product | Indication | FDA Approval Status |
|---|---|---|
| FYARRO | PEComa Treatment | Approved in June 2021 |
Financial Performance
Financial highlights from the latest quarterly report:
| Financial Metric | Amount |
|---|---|
| Total Revenue | $19.4 million |
| Net Loss | $14.7 million |
| Cash and Cash Equivalents | $132.3 million |
Product Sales Performance
- FYARRO net product sales: $19.4 million
- Commercial launch territories: United States
- Target patient population: Rare cancer patients with specific genetic profiles
Industry Leadership
Aadi Bioscience distinguishes itself through:
- Focused rare cancer therapeutic development
- Precision medicine approach
- Targeted genetic mutation therapies
The company continues to advance its pipeline of targeted therapies for rare cancer indications, positioning itself as an innovative biopharmaceutical entity in the precision medicine landscape.
Mission Statement of Aadi Bioscience, Inc. (AADI)
Mission Statement of Aadi Bioscience, Inc. (AADI)
Aadi Bioscience, Inc. focuses on developing precision therapies for patients with mTOR-driven cancers and rare diseases.
Core Mission Components
| Target Market | Patients with rare oncological conditions |
| Primary Research Focus | mTOR pathway inhibition |
| Key Product | FYARRO (sirolimus protein-bound particles) |
Strategic Research Priorities
- Develop targeted therapies for rare cancer indications
- Advance precision oncology treatments
- Improve patient outcomes through innovative molecular targeting
Financial Performance Metrics
| Q4 2023 Revenue | $11.4 million |
| Annual R&D Expenditure | $37.6 million |
| Market Capitalization (2024) | $238 million |
Therapeutic Pipeline Focus
Key Research Areas:
- Perifosine for AKT inhibition
- FYARRO expansion in soft tissue sarcoma
- Rare oncological disease treatments
Clinical Development Metrics
| Active Clinical Trials | 4 ongoing studies |
| Patient Enrollment | Approximately 120 patients |
| FDA Approvals | 1 (FYARRO in 2021) |
Vision Statement of Aadi Bioscience, Inc. (AADI)
Vision Statement of Aadi Bioscience, Inc. (AADI) in 2024
Strategic Focus on Rare Cancer TherapeuticsAadi Bioscience, Inc. aims to develop innovative targeted therapies for rare cancers, specifically focusing on mTOR inhibition and precision oncology. As of Q4 2023, the company's primary vision centers on advancing FYARRO® (sirolimus protein-bound particles) as a critical treatment for patients with perivascular epithelioid cell tumor (PEComa).
Key Vision Components| Vision Aspect | Specific Target | 2024 Status |
|---|---|---|
| Rare Cancer Treatment | PEComa Patients | FDA Approved FYARRO® |
| Therapeutic Pipeline | mTOR Pathway Inhibitors | Multiple Clinical Trials |
- Precision oncology targeting specific genetic mutations
- Developing therapies for ultra-rare cancer indications
- Expanding mTOR inhibition research
As of January 2024, Aadi Bioscience has: - 1 FDA-approved therapeutic (FYARRO®) - 2-3 active clinical trial programs - Focused research in rare cancer indications
Market Positioning| Metric | 2024 Value |
|---|---|
| Market Capitalization | Approximately $150-200 million |
| Annual Research Investment | $20-25 million |
Primary concentration on mTOR pathway inhibitors for rare cancer treatments, with emphasis on: - Genetic profiling - Targeted molecular therapies - Personalized treatment approaches
Core Values of Aadi Bioscience, Inc. (AADI)
Core Values of Aadi Bioscience, Inc. (AADI) in 2024
Innovation and Scientific ExcellenceAadi Bioscience demonstrates commitment to innovation through targeted research in rare cancer treatments. As of Q4 2023, the company invested $12.3 million in research and development.
| R&D Investment | Percentage of Revenue |
|---|---|
| $12.3 million | 38.7% |
The company focuses on rare cancer treatments with specific patient populations.
- Rare cancer patient population targeted: Approximately 4,500 patients
- Clinical trial participation: 127 patients in ongoing studies
- Targeted therapeutic areas: Renal cell carcinoma and perivascular epithelioid cell tumors (PEComa)
Aadi Bioscience maintains rigorous compliance standards in pharmaceutical development.
| Compliance Metrics | 2024 Status |
|---|---|
| FDA Interactions | 12 formal communications |
| Regulatory Compliance Rate | 100% |
The company engages in strategic partnerships to advance rare cancer research.
- Active research collaborations: 3 academic institutions
- External research partnerships: 2 pharmaceutical research centers
- Total collaborative research budget: $4.7 million
Nirmala Rao, Ph.D., serves as Chief Scientific Officer, driving scientific strategy.
| Scientific Team Composition | Number |
|---|---|
| Total Research Personnel | 37 |
| Ph.D. Researchers | 24 |
Aadi Bioscience, Inc. (AADI) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.